Promotility medications--now and in the future

Area of Science:

• Pharmacology
• Gastroenterology
• Drug Discovery

Background:

• Gastrointestinal (GI) promotility drugs enhance gastric emptying and bowel transit by stimulating smooth muscle contractions.
• Current prokinetic drug classes include antidopaminergic, serotonergic, and motilin-receptor agonists.
• Existing treatments exhibit moderate efficacy, suboptimal symptomatic responses, and adverse effects, highlighting a need for novel therapeutic agents.

Purpose of the Study:

• To address the unmet need for improved treatments for GI motility disorders.
• To explore the potential of new prokinetic drug classes currently under evaluation.
• To emphasize the importance of understanding pathophysiology in selecting candidate agents and designing clinical trials.

Main Methods:

• Review of current and emerging prokinetic drug classes.
• Analysis of the limitations of existing therapies.
• Discussion of challenges in developing new prokinetic agents due to incomplete understanding of motility disorders.

Main Results:

• Current prokinetic agents offer limited symptomatic relief and have associated side effects.
• Several novel prokinetic drugs and drug classes are in development.
• Lack of insight into the pathophysiology of GI motility disorders complicates the selection and trial design of new agents.

Conclusions:

• There is a significant need for new classes of prokinetic drugs with improved efficacy and safety profiles.
• Further research into the pathophysiology of GI motility disorders is crucial for advancing prokinetic drug development.
• Long-term efficacy studies are essential for evaluating candidate prokinetic drugs in chronic, relapsing GI motor disorders.